We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

215 hedge funds and large institutions have $2.23B invested in Ligand Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 59 increasing their positions, 89 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $23.5M | Put options by funds: $9.54M

138% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 21

29% more capital invested

Capital invested by funds: $1.73B → $2.23B (+$496M)

15% more funds holding

Funds holding: 187 → 215 (+28)

34% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 89

40% less funds holding in top 10

Funds holding in top 10: 10 → 6 (-4)

Holders
215
Holders Change
+28
Holders Change %
+14.97%
% of All Funds
5.79%
Holding in Top 10
6
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-40%
% of All Funds
0.16%
New
50
Increased
59
Reduced
89
Closed
21
Calls
$23.5M
Puts
$9.54M
Net Calls
+$14M
Net Calls Change
+$14.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$32.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$25.8M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$19.7M
4
GIM
Granahan Investment Management
Massachusetts
+$18.6M
5
JHIU
Janus Henderson Investors US
Colorado
+$10.8M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$24.1M
2
BI
BVF Inc
California
-$20.6M
3
Invesco
Invesco
Georgia
-$18M
4
RIM
RS Investment Management
California
-$17.9M
5
NCGI
Next Century Growth Investors
Minnesota
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAMS
51
Bellevue Asset Management (Switzerland)
Switzerland
$7.69M -$1.48M -27,202 -18%
Morgan Stanley
52
Morgan Stanley
New York
$7.45M +$5.74M +105,263 +804%
BBA
53
Baker Bros. Advisors
New York
$7.41M – – –
TCM
54
Timpani Capital Management
Wisconsin
$7.37M -$1.23M -22,571 -16%
TCIM
55
TIAA CREF Investment Management
New York
$7.33M -$450K -8,239 -7%
WC
56
Woodstock Corp
Massachusetts
$7.21M +$24.5K +449 +0.4%
BIM
57
BlackRock Investment Management
Delaware
$6.8M +$257K +4,715 +5%
Norges Bank
58
Norges Bank
Norway
$6.3M +$2.09M +38,270 +62%
CC
59
Cornerstone Capital
California
$5.96M +$2.89M +52,890 +126%
CLM
60
ClearBridge LLC (Maryland)
Maryland
$5.52M +$4.78M +87,636 New
California Public Employees Retirement System
61
California Public Employees Retirement System
California
$5.42M +$604K +11,061 +15%
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
$5.39M -$677K -12,399 -13%
Ohio Public Employees Retirement System (OPERS)
63
Ohio Public Employees Retirement System (OPERS)
Ohio
$5.33M -$1.71M -31,259 -27%
FLAM
64
First Light Asset Management
Minnesota
$4.96M -$3.7M -67,758 -46%
AP
65
AHL Partners
United Kingdom
$4.77M +$4.14M +75,814 New
BA
66
BlackRock Advisors
Delaware
$4.54M -$1.59M -29,051 -29%
Two Sigma Investments
67
Two Sigma Investments
New York
$4.45M -$3.64M -66,794 -49%
AllianceBernstein
68
AllianceBernstein
Tennessee
$3.91M -$87.5K -1,603 -3%
D.E. Shaw & Co
69
D.E. Shaw & Co
New York
$3.83M +$1.57M +28,816 +90%
ARTA
70
A.R.T. Advisors
New York
$3.68M +$3.19M +58,420 New
Comerica Bank
71
Comerica Bank
Texas
$3.65M +$1.61M +29,595 +104%
First Trust Advisors
72
First Trust Advisors
Illinois
$3.64M +$3.16M +57,852 New
CCM
73
Cadence Capital Management
Massachusetts
$3.63M +$3.15M +57,671 New
JAM
74
JW Asset Management
Florida
$3.62M +$71.6K +1,313 +2%
RI
75
Redwood Investments
Massachusetts
$3.52M +$1.03M +18,787 +51%
1 2
3
4 5

LGND Hedge Fund Activity: Q2 2015 in Review

215 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2015, worth a combined $2.23B — up 29% from $1.73B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new LGND positions and 21 closed out — a net gain of 29 holders — while 59 added to existing stakes and 89 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $32.1M. The largest seller was Goldman Sachs, cutting an estimated $24.1M.

  • 215 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2015, up from 187 in Q1 2015.
  • Funds reported $2.23B of Ligand Pharmaceuticals stock for Q2 2015, up 29% quarter-over-quarter.
  • 50 funds opened new Ligand Pharmaceuticals positions in Q2 2015 and 21 closed out, a net change of +29 holders.
  • The largest Ligand Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $32.1M added.
  • The largest Ligand Pharmaceuticals seller in Q2 2015 was Goldman Sachs, an estimated $24.1M sold.

Based on aggregated 13F filings for Q2 2015.